REG - Fusion Antibodies - Contract win

Fusion AntibodiesAnnouncement

27/02/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250227:nRSa6084Ya&default-theme=true

RNS Number : 6084Y  Fusion Antibodies PLC  27 February 2025

27 February 2025

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Contract Win

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, announces that it has been selected to proceed with a new stable
Cell Line Development project (the "CLD Project") under a collaborative
research and development agreement (the "Agreement") with a US based
biotechnology company (the "Client").

 

Work in relation to the CLD Project is expected to commence shortly and last
six to nine months. The Agreement is expected to result in Fusion generating
revenues in the region of US$250,000 by the end of 2025.

 

Adrian Kinkaid, CEO of Fusion, said: "We are delighted to have been selected
to generate the definitive cell line for the future production of this
important therapeutic product. We look forward to continuing to work with our
Client to bring better antibodies to the clinic more rapidly. The CLD Project
highlights the strong reputation that Fusion has for delivering high quality
therapeutic antibodies and their associated cell lines: a part of our offering
with excellent scope for growth.

 

"Whilst it is not anticipated that revenues from the new CLD Project will
substantially impact revenues in the current financial year, it provides a
valuable bedrock for the financial year ending 31 March 2026. We look forward
to continuing to build on the excellent relationship with our Client and to
repeating the success with more cell line development projects in the future."

 

Navigate to our Interactive Investor hub here:
https://investorhub.fusionantibodies.com/
(https://investorhub.fusionantibodies.com/) . Engage with us by asking
questions, watching video summaries and seeing what other shareholders have to
say.

 

Enquiries:

 

 Fusion Antibodies plc                                                          www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                             Via Walbrook PR

 Stephen Smyth, Chief Financial Officer

 Allenby Capital Limited                                             Tel: +44 (0) 20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 Shard Capital Partners LLP
 Damon Heath (Joint Broker)                                          Tel: +44 (0) 207 186 9952

 Walbrook PR                       Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                                                     Mob: +44 (0)7876 741 001

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the development of antibodies for
both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody generation,
development, production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx (TM) platform and the
production of antibody generating stable cell lines to provide material for
use in clinical trials. Since 2012, the Company has successfully sequenced
and expressed over 250 antibodies and successfully completed over 200
humanisation projects and has an international, blue-chip client base, which
has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion Antibodies provides
a broad range of services in antibody generation, development, production,
characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTEAPAKAANSEFA